Clinical Trials Arena on MSN
CalciMedica’s stock drops 75% on acute kidney injury trial termination
The biopharma will now evaluate how it can safely progress Auxora’s development in AKI.
Acute kidney injury (AKI), previously called acute renal failure, is when the kidneys are suddenly unable to filter waste products from the blood. This condition can develop slowly or quickly, and ...
CalciMedica had been evaluating the therapy, called Auxora, in the Kourage trial of patients with stage 2 or 3 AKI with ...
Presentation to Include Additional Positive Data from the Recently Completed PRIME Clinical Study - SAN DIEGO, CA / ...
A substantial proportion of patients admitted to hospitals in Italy experienced acute kidney injury (AKI), which was associated with worsened in-hospital mortality outcomes, longer hospital stays, and ...
CalciMedica shares fell after the company stopped its Phase 2 KOURAGE trial for Auxora due to safety concerns.
Hosted on MSN
Kidney Failure Symptoms, Causes, and Diagnosis
Kidney failure symptoms may begin so gradually that you don't really notice swelling, joint pain, or changes in how you urinate (pee). Or, you may think that itchy skin and other signs are due to ...
Investing.com -- CalciMedica Inc. (NASDAQ:CALC) stock plunged 80% Wednesday after the company announced it was discontinuing its Phase 2 KOURAGE clinical trial for acute kidney injury following safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results